FUNDAMENTAL AND CLINICAL STUDIES ON AB-206 IN UROLOGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 26; no. Supplement4; pp. 192 - 208
• Main Authors: KURODA, YASUJI, YAMAGUCHI, KINYA, KATAOKA, NOBUO, MITA, TOSHIHIKO, ISHIGAMI, JOJI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 25.09.1978
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.26.Supplement4_192

1. Antibacterial activities The MIC of AB-206 was determined for clinical isolates from the patients with various urinary tract infections. The peak of the MIC values was 0.78μg/ml for E. coli, 3.12μg/ml and 50μg/ml for Klebsiella, 25μg/ml and≥100μg/ml for Pseudomonas aeruginosa, 25μg/ml for Staphylococcus epidermidis and≥50μg/ml for Serratia. AB-206 gave better MIC values by 2-4 grades than NA and by 1-3 grades than PA for E. coli, and by 2 grades than NA and by 2-4 grades than PA for Klebsiella. As for Pseudomonas aeruginosa and Serratia, the compound showed nearly the same distribution of the MIC as NA and PA. It was inferior to NA and PA by 1 grade for Staphylococcus epidermidis. 2. Serum levels and urinary recovery rate AB-206 was orally given to 2 healthy male adults at a time of non-fasting in a single dose of 250 mg. The serum levels peaked at 2.9μ/ml after 2 hours. The levels gradually fell with the lapse of time, reaching under the determinable limit after 6 hours. The urinary levels reached a peak at 31.8μ/ml after 2-4 hours. The value at 6-8 hours was 1.53μ/ml. The urinary recovery rate during the first 8 hours averaged 3.12%. The serum levels and urinary recovery rate were also determined in 3 other healthy male adults who were given 250 mg of AB-206 4 times a day for 14 days. The serum levels reached a peak of less than 4.60μ/ml on days 1 and 14 without showing any tendency of retention. Comparison of one-hour values on individual days revealed no significant differences. The urinary levels and urinary recovery rate were nearly equal in all the 3 adults, averaging 4.7% on day 1 and 4.3% on day 14. 3. Clinical evaluation AB-206 was tried in 103 cases of various urinary infections. Its therapeutic effect was estimated as excellent in 70 cases, good in 18 cases and poor in 15 cases. The efficacy rate was 85. 4%. For the group of 82 cases with simple urinary tract infection, the therapeutic effect was excellent in 58 cases, good in 14 cases and poor in 10 cases, and the efficacy rate was 87.8%. For the group of 21 cases with complicated urinary tract infection, the therapeutic effect was excellent in 12 cases, good in 4 cases and poor in 5 cases, and the efficacy rate was 76.2%. 4. Side effec Only 4 (3.8%) out of the 103 cases treated with AB-206 complained of mild gastric disorder. No cases showed any unusual finding in the hepatic and renal function tests and of hematological tests conducted. No evidence of retention in the blood was seen with the drug continuously administered at 250 mg 4 times a day for 14 days.